Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 796 across all filing types
Latest filing 2025-11-06 Interim / Quarterly Rep…
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for Pharming Group N.V. covering the third quarter of 2025. It includes detailed financial statements (consolidated profit and loss), management commentary on business performance, product-specific revenue analysis (RUCONEST and Joenja), and organizational updates. It is not a mere announcement (RPA) or a short earnings release (ER), as it contains substantive financial data and detailed analysis of the company's operations for the specified period. Therefore, it is classified as an Interim/Quarterly Report. Q3 2025
2025-11-06 Dutch
Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the third quarter of 2025, titled 'Pharming Group reports third quarter 2025 financial results'. It contains detailed financial statements, including a Consolidated Statement of Income, segment revenue breakdowns, and a Consolidated Balance Sheet. It provides substantive financial analysis, management commentary, and operational updates. As it covers a period shorter than a full fiscal year and includes actual financial data, it is classified as an Interim/Quarterly Report (IR). Q3 2025
2025-11-06 English
6-K
Foreign Filer Report
2025-10-22 English
Pharming Group provides update on previously announced G&A expense reduction plan
Earnings Release Classification · 1% confidence The document is a press release from Pharming Group N.V. announcing a corporate restructuring plan, specifically a reduction in workforce and administrative costs. This type of announcement regarding organizational changes, management strategy, and operational updates that do not fit into specific financial reporting or shareholder meeting categories is best classified as a general regulatory filing or corporate announcement. Given the nature of the content (operational update), 'RNS' (Regulatory Filings) is the most appropriate category. Q4 2025
2025-10-07 Dutch
Pharming Group provides update on previously announced G&A expense reduction plan
Regulatory Filings Classification · 1% confidence The document is a press release announcing an organizational restructuring and a G&A expense reduction plan. It does not fit into specific categories like financial reports, dividend announcements, or director dealings. As it is a general corporate announcement regarding operational strategy and internal restructuring, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for miscellaneous corporate announcements that do not meet the criteria for more specific tags.
2025-10-07 English
6-K
Foreign Filer Report
2025-10-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.